pgsk–3β (ser9) antibody Search Results


pgsk3β (phospho ser9  (ImmunoWay Biotechnology Company)
90
ImmunoWay Biotechnology Company pgsk3β (phospho ser9
Effects of METTL3 overexpression on wnt/β‐catenin pathway and effects of activation of wnt/β‐catenin pathway on EMT process of cells overexpressing METTL3. A, Western blot analysis of the proteins of wnt/β‐catenin pathway, including <t>pGSK3β,</t> GSK3β, β‐catenin and cyclinD1, with or without treatment with TGFβ1 for 48 h B, Statistical analysis of the relative protein density, which was normalized to GAPDH. C, Western blot analysis of the epithelial marker ZO‐1 and mesenchymal marker N‐cadherin after treatment with TGFβ1 for 48 h. D, Statistical analysis of the relative protein density, which was normalized to GAPDH. F, Migration ability of ARPE‐19 cells after seeding with or without TGFβ1 for 24 h, as measured by the transwell assay. Scale bar: 100μm. E, Statistical analysis of the number of cells that migrated through the upper chamber. Statistical significance was determined by one‐way ANOVA, followed by Bonferroni's post hoc test for multiple comparisons (* P <.05, ** P <.01, **** P <.0001)
Pgsk3β (Phospho Ser9, supplied by ImmunoWay Biotechnology Company, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pgsk%E2%80%933%CE%B2+(ser9)+antibody/pgsk3%CE%B2++phospho+ser9+antibody/pmc08093987-90-42-46
Average 90 stars, based on 1 article reviews
pgsk3β (phospho ser9 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Effects of METTL3 overexpression on wnt/β‐catenin pathway and effects of activation of wnt/β‐catenin pathway on EMT process of cells overexpressing METTL3. A, Western blot analysis of the proteins of wnt/β‐catenin pathway, including pGSK3β, GSK3β, β‐catenin and cyclinD1, with or without treatment with TGFβ1 for 48 h B, Statistical analysis of the relative protein density, which was normalized to GAPDH. C, Western blot analysis of the epithelial marker ZO‐1 and mesenchymal marker N‐cadherin after treatment with TGFβ1 for 48 h. D, Statistical analysis of the relative protein density, which was normalized to GAPDH. F, Migration ability of ARPE‐19 cells after seeding with or without TGFβ1 for 24 h, as measured by the transwell assay. Scale bar: 100μm. E, Statistical analysis of the number of cells that migrated through the upper chamber. Statistical significance was determined by one‐way ANOVA, followed by Bonferroni's post hoc test for multiple comparisons (* P <.05, ** P <.01, **** P <.0001)

Journal: Journal of Cellular and Molecular Medicine

Article Title: METTL3 attenuates proliferative vitreoretinopathy and epithelial‐mesenchymal transition of retinal pigment epithelial cells via wnt/β‐catenin pathway

doi: 10.1111/jcmm.16476

Figure Lengend Snippet: Effects of METTL3 overexpression on wnt/β‐catenin pathway and effects of activation of wnt/β‐catenin pathway on EMT process of cells overexpressing METTL3. A, Western blot analysis of the proteins of wnt/β‐catenin pathway, including pGSK3β, GSK3β, β‐catenin and cyclinD1, with or without treatment with TGFβ1 for 48 h B, Statistical analysis of the relative protein density, which was normalized to GAPDH. C, Western blot analysis of the epithelial marker ZO‐1 and mesenchymal marker N‐cadherin after treatment with TGFβ1 for 48 h. D, Statistical analysis of the relative protein density, which was normalized to GAPDH. F, Migration ability of ARPE‐19 cells after seeding with or without TGFβ1 for 24 h, as measured by the transwell assay. Scale bar: 100μm. E, Statistical analysis of the number of cells that migrated through the upper chamber. Statistical significance was determined by one‐way ANOVA, followed by Bonferroni's post hoc test for multiple comparisons (* P <.05, ** P <.01, **** P <.0001)

Article Snippet: Western blot analysis was performed as described previously, The following are used as the primary antibodies: METTL3 (1:1000; Abcam, Cambridge, UK), N‐cadherin (1:10 000; Abcam, Cambridge, UK), αSMA (1:500; Sigma‐Aldrich Corp), ZO‐1 (1:500; Invitrogen, Carlsbad, CA, US), MMP9 (1:500; Abcam, Cambridge, UK), pGSK3β (phospho Ser9) (1:1000, Immunoway Biotechnology, Plano, US), GSK3β (1:1000, Immunoway Biotechnology, Plano, US), cyclinD1 (1:1000, Immunoway Biotechnology, Plano, US), β‐catenin (1:1000, Cell Signaling Technology), β‐actin (1:1000, Cell Signaling Technology) ，β‐tubulin (1:1000, Cell Signaling Technology) and GAPDH (1:1000; Cell Signaling Technology).

Techniques: Over Expression, Activation Assay, Western Blot, Marker, Migration, Transwell Assay